WHO Drug Information Vol. 18, No. 1, 2004
(2004; 109 pages) View the PDF document
Table of Contents
Open this folder and view contentsRegulatory Challenges
Open this folder and view contentsEssential Medicines
Open this folder and view contentsSafety and Efficacy Issues
Open this folder and view contentsVaccines and Biomedicines
Open this folder and view contentsHerbal Medicines
Open this folder and view contentsRegulatory and Safety Action
Close this folderConsultation Document
View the documentThe International Pharmacopoeia - monographs for antiretrovirals
View the documentIndinavir sulfate
View the documentNelfinavir mesilate
View the documentNevirapine anhydrous
View the documentProposed International Nonproprietary Names: List 90
View the documentRecommended International Nonproprietary Names: List 51
 

The International Pharmacopoeia - monographs for antiretrovirals

Within the framework of the Pilot Procurement Project for Quality and Sourcing of HIV Drugs (http://www.who.int/medicines), the International Pharmacopoeia is collaborating with manufacturers, independent analytical drug quality control laboratories, national and regional pharmacopoeial bodies, research, governments, and regulatory bodies to provide specifications and monographs for the following antiretroviral agents:

abacavir, didanosine, efavirenz, indinavir, lamivudine, nelfinavir, nevirapine, ritonavir, saquinavir, stavudine, zidovudine

Specifications for the respective dosage forms will be developed during a second phase of the project. The draft monographs, Indinavir sulfate, nelfinavir mesilate, and nevirapine are now available for consultation and are presented below. Comments should be sent to: Quality and Safety: Medicines, World Health Organization, 1211 Geneva 27, Switzerland or kopps@who.int.

to previous section to next section
 

Last updated: May 3, 2013